23 July 2020 : Clinical Research
Clinicopathological Analysis and Prognostic Assessment of Transcobalamin I (TCN1) in Patients with Colorectal Tumors
Xinqiang Zhu12ABCDEG*, Kui Yi3BE, Daorong Hou4ADF, Hailong Huang2BC, Xuetong Jiang2ABE, Xiaohong Shi2BCE, Chungen Xing1AEFDOI: 10.12659/MSM.923828
Med Sci Monit 2020; 26:e923828
Table 2 Relationship between TCN1 immunoexpression and clinicopathological characteristics in patients with colorectal cancer.
Parameters | TCN1 immunoexpression level | Statistical results | |||
---|---|---|---|---|---|
Low | Moderate | Strong | |||
Age | ≥65 | 6 | 18 | 21 | =−0.250; P=0.803=−0.039; P=0.806 |
<65 | 21 | 18 | 39 | ||
Sex | Female | 15 | 15 | 27 | =−0.369; P=0.712 |
Male | 12 | 21 | 33 | ||
CEA level | Increased | 6 | 9 | 36 | =−2.909; P=0.004=0.460; P=0.002 |
Normal | 21 | 27 | 24 | ||
CA125 level | Increased | 0 | 12 | 15 | =−1.043; P=0.297 |
Normal | 27 | 24 | 45 | ||
CA19-9 level | Increased | 3 | 3 | 18 | =−1.482; P=0.138 |
Normal | 24 | 33 | 42 | ||
Tumor location | Colon | 3 | 3 | 24 | (2.92)=4.525P=0.104 |
Distal colon | 9 | 9 | 9 | ||
Rectum | 15 | 24 | 27 | ||
Histological differentiation | G1 | 9 | 15 | 6 | (2.92)=4.976P=0.083 |
G2 | 15 | 9 | 24 | 1−2, 1–3=0.353; P=0.024 | |
G3 | 3 | 12 | 30 | ||
Depth of invasion | T1/T2 | 15 | 3 | 3 | =−2.821; P=0.005=0.446; P=0.003 |
T3/T4 | 12 | 33 | 57 | ||
Tumor size | ≤5 cm | 21 | 24 | 21 | =−2.341; P=0.01 9=−0.370; P=0.017 |
>5 cm | 6 | 12 | 39 | ||
Metastases to regional lymph nodes | No | 27 | 24 | 15 | =−3.845, p<0.001 |
Yes | 0 | 12 | 45 | ||
Nerve invasion | No | 21 | 18 | 36 | =−0.551; P=0.582 |
Yes | 6 | 18 | 24 | ||
Adjuvant chemotherapy | No | 1 | 2 | 2 | =−0.352; P=0.683 |
Yes | 36 | 38 | 44 | ||
CEA – carcinoembryonic antigen; CA125 – cancer antigen 125; CA19-19 – cancer antigen 19-9. |